Literature DB >> 12209530

Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice.

Hideo Yoshida1, Minoru Satoh, Krista M Behney, Chee-Gun Lee, Hanno B Richards, Victoria M Shaheen, Jun-Qi Yang, Ram R Singh, Westley H Reeves.   

Abstract

OBJECTIVE: This study examined the interactions between exogenous and endogenous factors shaping the phenotype of lupus in autoimmune (NZB x NZW)F(1) mice exposed to pristane, a model environmental trigger.
METHODS: Frequencies of various autoantibodies in untreated NZB/NZW mice were determined by various means (immunoprecipitation, enzyme-linked immunosorbent assay [ELISA], Crithidia luciliae kinetoplast staining). Pristane or saline was administered intraperitoneally to 9-12-week-old NZB/NZW mice, followed by serial studies of autoantibodies, total Ig levels (ELISA), and proteinuria (dipstick).
RESULTS: Besides antichromatin/DNA responses, NZB/NZW mice spontaneously produced novel autoantibodies against the double-stranded RNA binding protein RNA helicase A (RHA). In contrast, NZB/NZW mice (n = 70) did not produce autoantibodies against the nuclear RNP (nRNP), Sm, Ro, or La antigens. Pristane exposure synergistically activated the production of antichromatin/DNA antibodies and dramatically accelerated renal disease. Production of anti-nRNP/Sm and Su autoantibodies also was induced, indicating that the unresponsiveness of NZB/NZW mice to these antigens can be overcome. Curiously, pristane treatment did not enhance the production of anti-RHA, suggesting that these autoantibodies are regulated differently than anti-DNA/chromatin and Sm. In contrast to previous reports that suggest a critical role of deficient interleukin-12 (IL-12) production in the pathogenesis of lupus, there was overproduction of IL-12 in the peritoneal cavity of pristane-treated NZB/NZW mice, and their spleen cells also produced large amounts of IL-12.
CONCLUSION: These data lead us to propose that environmental influences exacerbate autoimmune manifestations in genetically lupus-susceptible mice through their stimulatory effects on proinflammatory cytokines, such as IL-12.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209530      PMCID: PMC2291543          DOI: 10.1002/art.10441

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  53 in total

1.  Epistatic modifiers of autoimmunity in a murine model of lupus nephritis.

Authors:  L Morel; X H Tian; B P Croker; E K Wakeland
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

2.  Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane.

Authors:  M Satoh; H B Richards; V M Shaheen; H Yoshida; M Shaw; J O Naim; P H Wooley; W H Reeves
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus.

Authors:  D A Horwitz; J D Gray; S C Behrendsen; M Kubin; M Rengaraju; K Ohtsuka; G Trinchieri
Journal:  Arthritis Rheum       Date:  1998-05

4.  Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain.

Authors:  D G Alleva; S B Kaser; D I Beller
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

5.  A role for RNA helicase A in post-transcriptional regulation of HIV type 1.

Authors:  J Li; H Tang; T M Mullen; C Westberg; T R Reddy; D W Rose; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

6.  Activities of adenovirus virus-associated RNAs: purification and characterization of RNA binding proteins.

Authors:  H J Liao; R Kobayashi; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

7.  Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus.

Authors:  M Satoh; J P Weintraub; H Yoshida; V M Shaheen; H B Richards; M Shaw; W H Reeves
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

Review 8.  Genetic susceptibility to systemic lupus erythematosus.

Authors:  T J Vyse; B L Kotzin
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

9.  Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice.

Authors:  G S Gilkeson; J Conover; M Halpern; D S Pisetsky; A Feagin; D M Klinman
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

10.  Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.

Authors:  H B Richards; M Satoh; M Shaw; C Libert; V Poli; W H Reeves
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more
  20 in total

1.  Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.

Authors:  Gerson Dierley Keppeke; Minoru Satoh; Maria Lucia Gomes Ferraz; Edward K L Chan; Luís Eduardo C Andrade
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

2.  Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice.

Authors:  Karen M Haas; Rei Watanabe; Takashi Matsushita; Hiroko Nakashima; Nobuko Ishiura; Hitoshi Okochi; Manabu Fujimoto; Thomas F Tedder
Journal:  J Immunol       Date:  2010-04-05       Impact factor: 5.422

3.  Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane).

Authors:  Dina C Nacionales; Kindra M Kelly; Pui Y Lee; Haoyang Zhuang; Yi Li; Jason S Weinstein; Eric Sobel; Yoshiki Kuroda; Jun Akaogi; Minoru Satoh; Westley H Reeves
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice.

Authors:  Donna L Thibault; Alvina D Chu; Kareem L Graham; Imelda Balboni; Lowen Y Lee; Cassidy Kohlmoos; Angela Landrigan; John P Higgins; Robert Tibshirani; Paul J Utz
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 5.  Animal models used to examine the role of the environment in the development of autoimmune disease: findings from an NIEHS Expert Panel Workshop.

Authors:  Dori Germolec; Dwight H Kono; Jean C Pfau; K Michael Pollard
Journal:  J Autoimmun       Date:  2012-06-27       Impact factor: 7.094

6.  Deficiency of the type I interferon receptor protects mice from experimental lupus.

Authors:  Dina C Nacionales; Kindra M Kelly-Scumpia; Pui Y Lee; Jason S Weinstein; Robert Lyons; Eric Sobel; Minoru Satoh; Westley H Reeves
Journal:  Arthritis Rheum       Date:  2007-11

7.  Inflammatory stimuli accelerate Sjögren's syndrome-like disease in (NZB x NZW)F1 mice.

Authors:  Umesh S Deshmukh; Yukiko Ohyama; Harini Bagavant; Xiaoti Guo; Felicia Gaskin; Shu Man Fu
Journal:  Arthritis Rheum       Date:  2008-05

8.  Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies.

Authors:  Claudia Azucena Palafox Sánchez; Minoru Satoh; Edward Kl Chan; Wendy C Carcamo; José Francisco Muñoz Valle; Gerardo Orozco Barocio; Edith Oregon Romero; Rosa Elena Navarro Hernández; Mario Salazar Páramo; Antonio Cabral Castañeda; Mónica Vázquez Del Mercado
Journal:  Arthritis Res Ther       Date:  2009-02-20       Impact factor: 5.156

9.  Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus.

Authors:  Donna L Thibault; Kareem L Graham; Lowen Y Lee; Imelda Balboni; Paul J Hertzog; Paul J Utz
Journal:  Arthritis Res Ther       Date:  2009-07-22       Impact factor: 5.156

10.  High prevalence of autoantibodies to RNA helicase A in Mexican patients with systemic lupus erythematosus.

Authors:  Monica Vázquez-Del Mercado; Claudia A Palafox-Sánchez; Jose F Muñoz-Valle; Gerardo Orozco-Barocio; Edith Oregon-Romero; Rosa E Navarro-Hernández; Mario Salazar-Páramo; Juan Armendariz-Borunda; Jorge I Gámez-Nava; Laura Gonzalez-Lopez; Jason Yf Chan; Edward Kl Chan; Minoru Satoh
Journal:  Arthritis Res Ther       Date:  2010-01-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.